Drug Profile
Research programme: bispecific therapeutics - Exscientia/Sumitomo Pharma
Latest Information Update: 05 Apr 2022
Price :
$50
*
At a glance
- Originator Exscientia; Sumitomo Dainippon Pharma
- Developer Exscientia; Sumitomo Pharma
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified